|
|
Post by mnholdem on May 23, 2018 21:00:04 GMT -5
Professor German is partially correct about genetic propensity, but he failed to recognize that the beta cells can recover if supported. HOWEVER, that is not true in all cases. Early Short-Term Intensive Insulin therapy has achieved remission in ~50% of trial patients, but that leaves another 50% that still had difficulties. The causes of diabetes are so varied and complex that there could be multiple reasons why. There's more than genetics involved.
Still, early STII has the potential to help millions of people. It deserves to be the first step in the Standards of Care for Diabetes.
|
|
|
|
Post by mnholdem on May 23, 2018 20:03:55 GMT -5
They reversed the titles! I must take a moment to publicly correct my exalted administrator and point out that two gentlemen in question did NOT have their titles exchanged. Both were correctly identified as "Dr."
What was mixed up were the captions underneath the photos. I feel it's my duty to point this out, since our ProBoards Administrator liane once publicly corrected me related to one of my posts by explaining the difference between highball and lowball glasses... a kindness for which I am forever indebted (and less intoxicated).
   
P.S. How THAT for a good memory, boss?
|
|
|
|
Post by mnholdem on May 23, 2018 14:00:11 GMT -5
Actually, joey, you would be violating the board rules with that continuous font selection. I suggest that you use it only for the words "Vegas" or "Knights".
|
|
|
|
Post by mnholdem on May 23, 2018 11:08:52 GMT -5
MannKind's Booth #403 is located at the hall entrance near the Product Theatre (image lower left). Not a bad location, IMO. 
|
|
|
|
Post by mnholdem on May 23, 2018 10:49:58 GMT -5
|
|
|
|
Post by mnholdem on May 22, 2018 17:00:49 GMT -5
I expect hedge fund managers to try and drive MNKD down right up to ADA2018 to stay near a good exit point, just in case. It may be a fight, though, as other traders start buying into the rumors.
|
|
|
|
Post by mnholdem on May 22, 2018 16:06:41 GMT -5
So, in other words, publications should lay it out in laymen's terms - excellent TIR control with statistically significant reduction of severe hypos - and back it up with the scientific detail for those HCPs who are so inclined to dig into the science.
One thing I've noticed about seasoned thought leaders, like Dr. Kendall, is that they can simplify complex analysis. I'm sure that the attendees at the ASM noticed that MannKind's CMO has that skill.
|
|
|
|
Post by mnholdem on May 22, 2018 15:56:37 GMT -5
Joey, we may as well add Israel to that list. MannKind just received the patent a few weeks ago on their 2016 application for the inhaler device (aka Dreamboat).
|
|
|
|
Post by mnholdem on May 22, 2018 14:45:00 GMT -5
I did. I read every post. My comment above was not about STAT but rather the late-breaking poster. I thought you were attempting to hijack the discussion with your reply to Sports' post. Sorry.
|
|
|
|
Post by mnholdem on May 22, 2018 14:38:06 GMT -5
I wouldn't rule out a new class of insulin either.
|
|
|
|
Post by mnholdem on May 22, 2018 14:24:47 GMT -5
...minus the $40 Monopoly cigar, of course.
|
|
|
|
Post by mnholdem on May 22, 2018 14:21:22 GMT -5
Seems to me, before you butted in, that we were talking about how presentations at ADA2018 could positively affect insurer coverage.
But you've only changed the course of the discussion to the next step in the progression. Improved adoption by endos and payers should lead to sales growth.
|
|
|
|
Post by mnholdem on May 22, 2018 14:11:13 GMT -5
Evangelist? Start living in reality. That's what all evangelists say. ;-) |
|
|
|
Post by mnholdem on May 22, 2018 11:27:18 GMT -5
Ask your doctor if Afrezza is right for you. 
|
|
|
|
Post by mnholdem on May 21, 2018 15:24:03 GMT -5
You could be right about STAT but the word is that MannKind's late-breaking poster at ADA2018 will show a significant reduction of severe hypo events. That would mean less of those costly EMT and emergency room visits. That has direct and short-term cost benefits to insurers and would capture their attention, IMHO.
|
|
